ZMYM2-FGFR1 fusion as secondary change in acute myeloid leukemia

Gene fusions in hematopoietic malignancies are often primary drivers that define many aspects of these diseases. For example, BCR-ABL1 fusion is a diagnostic marker that encodes a therapeutic targe...

[1]  S. Verstovsek,et al.  Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  V. Najfeld,et al.  Myeloid/lymphoid neoplasms with FGFR1 rearrangement , 2018, Leukemia & lymphoma.

[3]  Massimo Cristofanilli,et al.  Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application , 2016, Oncotarget.

[4]  W. Hofmann,et al.  Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes , 2015 .

[5]  Razelle Kurzrock,et al.  The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.

[6]  P. Koduru,et al.  Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: a case report and review of literature. , 2015, American journal of clinical pathology.

[7]  K. Döhner,et al.  Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. , 2015, Blood.

[8]  S. Baruchel,et al.  Late‐appearing Philadelphia chromosome in childhood acute myeloid leukemia , 2008, Pediatric blood & cancer.

[9]  H. Kantarjian,et al.  Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia , 2008, Leukemia.

[10]  K. Theil,et al.  The Philadelphia chromosome as a secondary abnormality in inv(3)(q21q26) acute myeloid leukemia at diagnosis: confirmation of p190 BCR-ABL mRNA by real-time quantitative polymerase chain reaction. , 2006, Cancer genetics and cytogenetics.

[11]  D. Fabbro,et al.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Reiter,et al.  The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of FGFR1 , 2002, Acta Haematologica.

[13]  A. Levis,et al.  A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p. , 2002, The hematology journal : the official journal of the European Haematology Association.

[14]  J. Aster,et al.  ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain. , 2000, Blood.

[15]  H. Drexler,et al.  Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. , 1993, Leukemia & lymphoma.